Valuation: Orexo AB

Market Cap 520M 54.51M 47.08M 44.3M 40.26M 75.73M 5.22B 76.84M 204M 2.61B 205M 200M 8.7B P/E 2026 *
-1.42x
P/E 2027 * -2.04x
Enterprise Value 415M 43.5M 37.57M 35.35M 32.13M 60.42M 4.17B 61.31M 162M 2.08B 163M 160M 6.94B EV / Sales 2026 *
21.8x
EV / Sales 2027 * 13.7x
Free-Float
78.37%
Yield 2026 *
-
Yield 2027 * -
1 day-2.15%
1 week-6.65%
Current month-0.68%
1 month-11.41%
3 months-22.34%
6 months-44.17%
Current year-51.50%
1 week 14.38
Extreme 14.38
15.9
1 month 13.7
Extreme 13.7
16.76
Current year 13.7
Extreme 13.7
36
1 year 13.7
Extreme 13.7
43.4
3 years 9.18
Extreme 9.18
43.4
5 years 8.44
Extreme 8.44
43.4
10 years 8.44
Extreme 8.44
87.9
Manager TitleAgeSince
Chief Executive Officer 54 2013-02-04
Director of Finance/CFO 59 2022-08-31
Chief Tech/Sci/R&D Officer - 2024-09-30
Director TitleAgeSince
Director/Board Member 64 2001-12-31
Director/Board Member 70 2019-04-10
Director/Board Member 62 2022-03-31
Date Insider Type Main position Quantity % Market Cap.
9/4/25 Buy

Chief Executive Officer

6 0.0000%
9/4/25 Free

Chief Executive Officer

1,393 0.0040%
9/3/25 Free 149 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-2.15%-6.65%-30.48%-16.19% 54.51M
-0.59%+3.64%+60.50%+23.78% 333B
+0.99%-1.29%+24.56%-12.50% 68.84B
+1.83%+2.21%+52.10%+142.46% 11.9B
+0.99%-0.10%-2.45%+0.25% 8.41B
-2.41%-5.86%-14.11%-1.50% 4.72B
-4.90%-7.01%-29.99%+14.02% 4.2B
-20.00%-18.20%-19.25%+23.55% 3.48B
+1.57%+4.59%+14.05%+58.31% 2.85B
+0.24%-4.18%-6.50%-3.33% 2.19B
Average -1.55%-2.20%+4.84%+22.89% 44.01B
Weighted average by Cap. +6.32%+2.21%+50.51%+20.58%

Financials

2026 *2027 *
Net sales 19M 1.99M 1.72M 1.62M 1.47M 2.77M 191M 2.81M 7.45M 95.52M 7.48M 7.32M 318M 27.5M 2.88M 2.49M 2.34M 2.13M 4.01M 276M 4.07M 10.78M 138M 10.83M 10.6M 460M
Net income -375M -39.34M -33.98M -31.97M -29.06M -54.65M -3.77B -55.45M -147M -1.89B -148M -144M -6.28B -270M -28.38M -24.51M -23.06M -20.96M -39.42M -2.72B -40M -106M -1.36B -107M -104M -4.53B
Net Debt -105M -11.02M -9.51M -8.95M -8.14M -15.3M -1.06B -15.53M -41.15M -528M -41.36M -40.46M -1.76B -143M -15M -12.96M -12.19M -11.08M -20.84M -1.44B -21.14M -56.04M -719M -56.32M -55.1M -2.39B
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
61
Date Price Change Volume
26-08-19 SEK 14.60 -1.88% 35,812
26-08-18 SEK 14.88 -4.86% 26,580
26-08-17 SEK 15.64 +2.89% 2,202
26-08-14 SEK 15.20 -2.94% 13,080
26-08-13 SEK 15.66 +0.13% 22,726
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise